NEW YORK, February 6, 2017 /PRNewswire/ --
On Friday, February 03, 2017, US marketssaw broad based gains with all sectors finishing the trading sessions in green. Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 5,666.77, up 0.54%; the Dow Jones Industrial Average edged
Cranbury, New Jersey-based Palatin Technologies Inc.'s stock advanced 5.86%, to close the day at $0.44. The stock recorded a trading volume of 8.50 million shares, which was above its three months average volume of 2.62 million shares. The Company's shares are trading 15.23% and 17.36% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have a Relative Strength Index (RSI) of 45.17. Visit us today and download your complete report on PTN for free at:
On Friday, shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. ended the session 1.84% higher at $22.10 with a total volume of 1.21 million shares traded. Shares of the Company, which provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the US, are trading at a PE ratio of 63.32. The stock is trading 27.26% below its 50-day moving average and 14.78% below its 200-day moving average. Moreover, the Company's shares have an RSI of 32.09.
On January 11th, 2017, research firm Needham downgraded the Company's stock rating from 'Buy' to 'Hold'. The complimentary research report on AMAG can be accessed at:
On Friday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. recorded a trading volume of 1.76 million shares, which was higher than their three months average volume of 955,240 shares. The stock ended the day 2.12% lower at $142.02. The Company's shares are trading at a PE ratio of 60.38. IDEXX Labs' stock has surged 22.48% in the last one month and 34.69% in the previous three months. Furthermore, the stock has rallied 100.25% in the past one year. The Company is trading below its 50-day and 200-day moving averages by 18.93% and 34.99%, respectively. Furthermore, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide, have an RSI of 83.05.
On February 03rd, 2017, research firm Feltl & Co. downgraded the Company's stock rating from 'Hold' to 'Sell'. Register for free on Stock-Callers.com and download the PDF research report on IDXX at:
New York headquartered Delcath Systems Inc.'s stock finished Friday's session 4.74% higher at $0.32 with a total volume of 4.98 million shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 71.23% and 98.73%, respectively. Shares of Delcath Systems, which operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver, have an RSI of 26.25. Get free access to your research report on DCTH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All